F S&P 500
5,256.50 +10.25 (+0.20%) F Dow Jones
39,703.00 +61.00 (+0.15%) F Nasdaq
18,305.00 +50.00 (+0.27%) E-mini Russell 2000 Index Futur
2,079.30 +11.40 (+0.55%) Petróleo
78.84 +0.58 (+0.74%) Oro
2,353.10 -21.90 (-0.92%)
Biocon Limited (BIOCON.NS)
Biocon Limited
20th KM, Hosur Road
Electronic City
Bengaluru 560100
India
91 80 2808 2808
https://www.biocon.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 16,545
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. | Founder & Executive Chairperson | 30M | N/D | 1953 |
| Mr. Siddharth Mittal BCom, CA, CPA | MD, CEO & Director | 47.88M | N/D | 1978 |
| Mr. Peter James Jonathan Bains | Group Chief Executive Officer | 3.28M | N/D | 1957 |
| Mr. Arun Gupta | Head of Operations | N/D | N/D | N/D |
| Mr. Atanu Roy | Group Chief Information Officer | N/D | N/D | N/D |
| Mr. Saurabh Paliwal | Head of Investor Relations | N/D | N/D | N/D |
| Mr. Mayank Verma | Company Secretary & Compliance Officer | 5.75M | N/D | N/D |
| Ms. Seema Shah Ahuja BA, MBA | Global Head of Communications & Corporate Brand | N/D | N/D | 1966 |
| Ms. Maninder Kapoor Puri | Head of Human Resources | N/D | N/D | 1973 |
| Mr. Paul Vazhayil Thomas | Chief Commercial Officer, U.S. & Portfolio Strategy & Business Dev, Adv mkts of Biosimilars Business | N/D | N/D | 1973 |
Descripción
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.
Gestión corporativa
La calificación ISS Governance QuickScore de Biocon Limited a partir del 1 de mayo de 2024 es 4. Las puntuaciones principales son Auditoría: 7; Junta: 2; Derechos del accionista: 1; Compensación: 9.
